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Abstract
Notch signaling is essential for the development of T cell progenitors through the interaction of NOTCH1 receptor on
their surface with the ligand, Delta-like 4 (DLL4), which is expressed by the thymic epithelial cells. Notch signaling is
quickly shut down once the cells pass β-selection, and CD4/CD8 double positive (DP) cells are unresponsive to
Notch. Over the past two decades a number of papers reported that over-activation of Notch signaling causes T cell
acute lymphoblastic leukemia (T-ALL), a cancer that prominently features circulating monoclonal CD4/CD8 double
positive T cells in different mouse models. However, the possible outcomes of Notch over-activation at different
stages of T cell development are unknown, and the fine timing of Notch signaling that results in T-ALL is poorly
understood. Here we report, by using a murine model that ectopically expresses DLL4 on developing T cells, that the
T-ALL onset is highly dependent on a sustained Notch activity throughout the DP stage, which induces additional
mutations to further boost the signaling. In contrast, a shorter period of Notch activation that terminates at the DP
stage causes a polyclonal, non-transmissible lymphoproliferative disorder that is also lethal. These observations
resolved the discrepancy of previous papers on DLL4 driven hematological diseases in mice, and show the critical
importance of the timing and duration of Notch activity.
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Introduction
The Notch pathway is highly conserved in multicellular
eukaryotes and essential in controlling spatial patterning,
morphogenesis and homeostasis in embryonic and adult
tissues [1,2].
The Notch pathway involves five ligands, four NOTCH
receptors, and sequential proteolytic processing of the ligand-
bound receptors to generate active Notch intracellular domain
(NICD), a process in which the proteolytic activity of γ-
secretase is crucial [1,3]. We have shown that combined
deletion of the two proteolytic subunits of the γ-secretase
complex, presenilins 1 and 2 (PS1 and PS2), results in
complete ablation of Notch activity in T-cells [4]. Once NICD is
generated, a transcriptional program is executed, which
includes Hes and Hey family members, Deltex-1 or Myc,
depending on cell type and context [5].
The thymus provides a unique environment for T cell
development [6]. T cell development starts when an early
progenitor enters the thymus and interacts with thymic
epithelial cells (TEC) expressing Delta-like ligand 4 (DLL4)
[7,8]. When DLL4 is not expressed on TEC, T cell development
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is abrogated. Enforced expression of NICD in hematopoietic
stem cells (HSC) bypassed the elimination of DLL4 in TEC [7].
DLL4 induces T cell commitment exclusively via interaction
with the Notch1 receptor [9]. The Notch pathway is essential for
T cell development until β selection [10-12] but after that stage
it is dispensable [4,12].
In mammals, NOTCH was discovered as the T cell receptor
partner of a chromosomal translocation that resulted in T-ALL
[13]. Since then, the Notch pathway has been linked to several
types of cancer, and, depending on the tissue, can function as
an oncogene [14-17], as a tumor suppressor [18,19], or even
have both roles, depending on which Notch receptor is
inactivated [20,21]. T-ALL is probably the most studied Notch-
mediated cancer [22,23], with NOTCH1-activating mutations
found in about 50% of T-ALL patients [24], and 8-12%
displaying mutations in FBW7, a molecule involved in the
degradation of NICD [25,26] . However, while a hyperactive
NOTCH pathway is observed in virtually all T-ALL cases, a
subset of patients does not have pathway-activating mutations
in NOTCH1 or FBW7, or the TCR: NOTCH1 translocation;
despite extensive analyses, no other mutations in the Notch
pathway have been linked to T-ALL in human patients [27,28].
Two laboratories reported the reconstitution of mice with
bone marrow cells ectopically expressing DLL4 [29,30].
Surprisingly, the outcomes were very different. While the report
of Yan et al, showed a transferable clonal T-ALL in 60% of the
recipients, the work by Dorsch et al showed a non-clonal non-
transferable lymphoproliferative disease.
In this report, we present two new mouse models. One is
called Tg8, in which DLL4 is ectopically expressed, under the
transcriptional control of the TCRα, on the surface of
developing and mature T cells beginning at the DP stage. All
Tg8 mice succumb to T-ALL at a young age. The second
mouse model is Tg8 crossed with Presenilin conditional
(floxed) knock-out and CD4-cre mice (Tg8 PS KO CD4-Cre). In
this model, Notch signaling is genetically abrogated at the DP
stage. These DP cells do not become transformed and T-ALL
does not occur. However, due to ectopic Notch signaling on
precursors outside the thymus, there is an uncontrolled
accumulation of polyclonal DP cells that results in massively
enlarged secondary lymphoid organs. These results define an
exquisite developmental window for Notch signaling effects,
and help explain the discrepancy between the previous reports
on DLL4 induced hematological diseases [29,30].
Materials and Methods
Ethics Statement
All procedures were approved by New York University’s
Institutional and Animal Care Use Committee (IACUC).
Mice
Tg8 mice were generated as described, using the same
MBP-specific TCRα construct [31].
Tg8 mice and control Tg5 mice were generated with exactly
the same TCRα DNA preparation, by microinjection into
C57BL/6 fertilized eggs.
PS1fl/fl PS2-/- (PS KO) CD4-Cre mice were previously
described [4]. Tg8 PS KO CD4-Cre mice were generated by
crossing the two aforementioned strains. Nu/nu B6 and B6
mice were purchased from Jackson labs (Bar Harbor, ME).
Antibodies and stainings
Thymocytes and splenocytes were stained and run through
BD LSRII. Data were analyzed with the FloJo software (Tree
Star). Antibody list is provided below.
BrdU labeling and Propidium Iodide (PI) staining
BD Pharmingen BrdU Flow Kits were used for BrdU staining.
Mice were injected i.p with 1mg of BrdU in PBS and sacrificed
4 hours later. Single cell suspensions were prepared form
thymus, spleen, and mesenteric LN. For PI staining, we
followed established procedures [32].
Real time PCR
RNA was extracted using Trizol Reagent (Invitrogen)
according to manufacture’s instructions. Total RNA was
reverse transcribed into cDNA using SuperScript Reverse
Transcriptasae II (Invitrogen). Primers are listed below.
Notch1 and Fbw7 sequencing
cDNA was synthesized from Tg8 pre-tumoral and tumoral
spleens. PCR primer listed below.
Dll4 knock-down, Bone Marrow infection, T cell
transduction
Dll4 shRNA was ligated into pQXIP-GFP. The same amount
of empty vector was transfected as a control. BM cells were
cultured in Optimen with SCF, FLT3L, IL6 and IL7 for 24 hrs
before infection. Virus supernatants were collected and added
to BM cultures. Two days later, 5x106 GFP+ cells were injected
i.v into RAG1-/- recipients.
Antibodies
anti-CD4 (clone H129.19, BD bioscience), anti-CD8 (53-6.7,
Biolegend), anti-DLL4 monoclonal antibody (mAb) YM152F:
courtesy of Dr. M. Yan, Genentech; final staining concentration:
1 μg/mL, Goat F(ab’)2 anti-human Ig(gamma)-PE as secondary
antibody (Invitrogen, H10104), anti-Notch1 (HMN1-12,
Biolegend), anti-NICD (mN1A, eBioscience, an antibody that
reacts with the intracellular domain of Notch1 but has very low
affinity for full-length Notch1) [33]. For intracellular Notch1
staining, cells were fixed and permeabilized using eBioscience
Fixation and Permeabilization Kit, followed by incubation with
10μg/ml mN1A at room temperature for 30 minutes. anti-Vβs:
Vβ3 (JOVI.1, Caltag), 4(KT4, Caltag), 5.1/5.2 (MR9-4,
PharMingen), 6(RR4-7, BD), 7(TR310, Caltag), 8.1/8.2 (MR5-2,
BD), 8.3(1B3.3, PharMingen), 9 (MR10-2, BD), 12(KT12,
Caltag), 13(mr12-3, BD) and 14(14-2, PharMingen), anti-CD25
(PC61.5, eBioscience), F4/80 (BM8, Biolegend), CD45
(Biolegend #103128; Clone: 30-F11). For
immunohistochemistry, the following antibodies were used:
anti-CD4 Alexa 647(Biolegend #100531; clone: RM4-5), anti-
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CD8 Alexa 488 (Biolegend #100723; clone: 53-6.7), anti-CD4
615 (eBioscience #42-0042-80; clone: RM4-5)
FoxN1 polymorphism PCR
PCR was performed to determine the polymorphism in the
FoxN1 gene. After PCR, the product was digested with Bsaj 1
for 2 hours at 60°C. The sample was analyzed by
electrophoresis in a 4% Nusieve agarose gel. When indicated,
CD4 cells were purified by MACS using Miltenyi reagents and a
Vario MACS apparatus (Miltenyi Biotec, Auburn, CA) following
the manufacturers’ instructions.
Primers
For real-time PCR
Dll4 F: CGCCAGGAAACTCTCTCATC; R:
TCATTTTGCTCGTCTGTTCG
Hes-1 F: TGTCTGCCTTCTCTAGCTTGG; R:
GCGAAGGGCAAGAATAAATG
Hey1 (Hrt-3) F: CACTTGAAGATGCTCCATGC;
R: TTCCCGAAACCCAATACTCC
Deltex-1 F: GAGGTCCACCAGCGTCAG; R:
GCCAGTGCCATTCAAGTTCT
Notch1 F: CATCCGTGGCTCCATTGTCTACC;
R: AGGCTCCACCGGCTCACTCTT
Notch3 F: TTCCCAGCGAGCATCCTTATTTGA
R: AGTTGCTGGGCTAGGTGTTGAGTC
For Notch1 and Fbw7 sequencing
Notch1
Exon 25-29 F: CCTCTTTGATGGCTTCGACT; R:
AGCACCATCTGAGGCATTCT.
Exon 34 3’F: GTGAGCTCGGCAGCCAAT; R:
CCAGGAAAATCAAGGCTCTG.
Exon 34 5’ F: AGCACTGGCTGGAGGTAGC; R:
GAGGATGGCAGTGATGTGG.
Fbw7
Exon 9-10 F:GGCAACCGCATAGTTAGTGG; R:
GAGATCCACTCACCACATGG
Exon 12 F: CTGGGAATGCAGATTCTACAG; R:
TATTGTCTACACAGTTGGAC
Ptcra (pre-Tα)a F: AATAGATCTCTACCATCAGGCATCGCT
R: AATCCGCGGCTACTGGAGGTGCTGGCCCGC
Ptcra (pre-Tα)b F: AATAGATCTCTACCATCAGGGGAATCT
R: AATCCGCGGCTACTGGAGGTGCTGGCCCGC
TCR Cα F: TGTTCACCGACTTTGACTCC; R:
TGGCGTTGGTCTCTTTGAAG
Statistical Analysis
Every experiment had multiple repeats (>3 times) with at
least 3 animals each time. Statistical analysis were conducted
with GraphPad Prism software. The Student's unpaired t test
was used as statistical test for significance. p values < 0.05
was considered significant. Error bars denote ± SEM.
Results
Tg8 mice spontaneously develop T cell lymphomas
with early onset and 100% penetrance
Tg8 mice were generated from the making of a series of
myelin basic protein - specific T cell receptor (MBP-TCR)
transgenic mice. The MBP-TCRα genomic construct is a 40 kb
Va4-Ja48 and contains promoter, enhancer and silencer
elements required for tissue specific expression in the T cell
lineage. The construct was inserted at random sites of the
genome to generate a series of Transgenic (Tg) mouse lines.
In one line, which was named Tg8, the construct was inserted
on Chromosome 2. We determined that the exact insertion site
had 100 percent correlation with probes D2Mit164 and
D2Mit423 (MIT/Whitehead Genome Center), located in
chromosome 2 at 71 cM and 68.9 cM. Interestingly, we
observed spontaneous T cell lymphomas (TCL) in all Tg8 mice
(Figure 1A), but not in mice that have the same TCRα
transgene inserted into a different chromosome (Tg5). In Tg8
mice, enlarged inguinal or axillary lymph nodes were palpable
at about 3 months of age. Approximately one month after that,
all mice died (Figure 1A). Tg8 lymphomas were clonal, i.e.
virtually all T cells of a given mouse expressed the same TCRβ
chain, and the selection of the Vβs appeared to be stochastic
(Figure S1A). TCL were transferrable (see below). All Tg8 TCL
co-expressed CD4 and CD8 (CD4+CD8+ double positive or DP)
to different degrees (Figure S1B). The high frequency of
circulating DP cells at later stages (>>25%) makes Tg8 a
spontaneous model of T cell acute lymphoblastic leukemia (T-
ALL). At the cytogenetic level, no aneuploidies or
translocations were found in Tg8 tumors (Figure 1B), indicating
no major genomic instability. No tumor arose in other tissues.
Only one copy of the TCRα transgene was inserted in Tg8
DNA (Figure S1C, left and central). The size of the TCRα
transcript was not altered by the insertion (Figure S1C, right).
Ectopic expression of Delta-like ligand 4 (DLL4) on the
surface of Tg8 T cells
The TCRα genomic construct used in the making of Tg8
mice contains promoter, enhancer and silencer elements
required for tissue specific expression in the T cell lineage
[34-37] (Figure 1C and Figure S1D). These transcriptional
regulatory elements could regulate the expression of the genes
surrounding the insertion site in Tg8 T cells. We therefore
cloned and sequenced the transgene insertion site and
assessed transgene-associated changes in expression of all
neighboring genes (Figure S1E and S1F). Dll4 mRNA was
elevated about 100-fold in T cells (but not B cells) from Tg8
mice, higher than the positive control of Dll4 expression,
vascular endothelial cells (Figure S1F). The overexpression of
Dll4 was confirmed by northern blot, which also indicated that
Dll4 mRNA size was unchanged in Tg8 mice. (Figure 1D). Only
the lymphoid organs expressed high level of Dll4 (Figure 1E).
Surface staining with anti-DLL4 antibodies showed that αβ T
cells expressed DLL4, but not γδ T cells, dendritic cells,
macrophages, natural killer cells or B cells (Figure 1F).
The expression of none of the other neighboring genes was
altered in a way comparable to Dll4 (Figure S1E and S1F).
DLL4 Expression at DP Stage Is Crucial for T-ALL
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Chac1 expression was upregulated in Tg8 T cells, but still
remained at a very low level, well below that of Chac1-
expressing skin Langenhans cells (Figure S1F).
Lmo2 gene is located more than 10 Mb form the Tg8
transgene insertion site on mouse Chromosome 2.
Nevertheless, we tested expression levels of Lmo2 due to its
relevance in lymphomagenesis [38], and observed that Lmo2
expression was not affected (Figure S1E).
In the thymus of pre-tumoral Tg8 mice, the main thymic
subpopulations had a relatively normal distribution (Figure 2A).
DLL4 surface expression was negative in CD4-CD8- double-
negative (DN) cells, began at the DP stage and was
maintained in both CD4 single positive (SP) and CD8 SP cells
(Figure 2B, left). Preceding surface expression, Dll4 mRNA
Figure 1.  Tg8 mice develop T-ALL due to over-expression
of Dll4 gene on T cells.  A) Enlarged hematopoietic organs
(spleen, mesenteric lymph node and thymus) but not non-
hematopoietic organ (kidney) of 4 month-old Tg8 mice
compared with WT (left panel). Survival curve of Tg8 mice
compared to WT and Tg5 mice (right panel). B) No obvert
aneuploidy in Tg8 lymphomas. On the right panel, a
metaphasic spread of one lymphoma; the left panel shows the
chromosomes cut from the right side picture and positioned
according to their size. Representative of 10 mice. C) Position
and orientation of TCRα transgene and Dll4 gene in mouse
Chromosome 2. D) Northern blot of Dll4 mRNA expression in
Tg8 and WT thymocytes. The same membrane was reblotted
with a probe of β actin as a loading control. E) qPCR analysis
of Dll4 mRNA expression in Tg8 pre-tumoral thymus, spleen,
mesenteric lymph nodes (mLN), skin, heart, kidney, liver and
brain compared to WT mice. The abundance is calculated as
the relative transcription normalized to β-actin expression fixed
at 10,000 (left). F) DLL4 expression is restricted to αβ T cells.
Flow cytometry analysis of DLL4 surface expression co-stained
with anti-αβ TCR (αβ T cells), anti-γδ TCR (γδ T cells), anti-
F4/80 (macrophages), anti-CD11c (dendritic cells), anti-CD19
(B cells) and anti-NK1.1 (NK cells), obtained from spleens of 4
week-old pre-tumoral Tg8 mice and WT littermates.
Representative of 5 mice.
doi: 10.1371/journal.pone.0084841.g001
was expressed at the DN4 stage (Figure 2B, right). In pre-
tumoral spleens, red pulp and white pulp zones were readily
found, and the white pulp retained well-defined T and B cell
zones (Figure 2D). Interestingly, from a young age, much
before the tumoral stage, there were CD4+CD8+ (DP) cells in
circulating blood and spleens of Tg8 animals, as assessed by
flow cytometry (Figure 2C) and immunohistology (Figure 2D
and 2E). The percentage of B cells was normal (Figure S1G).
In the periphery, CD4 SP, CD8 SP and DP cells all expressed
DLL4 on their surfaces (Figure 2F).
Figure 2.  Characterization of Tg8 cells.  A) Pre-tumoral Tg8
and WT thymus have similar distribution of the major
lymphocyte populations (DN, DP, CD4 SP and CD8 SP).
Representative of more than 20 mice. B) Surface DLL4
staining of the major thymic populations shown in Figure 1F
(left) and mRNA level of Dll4 in DN, DP and SP thymocytes
calculated by real-time PCR (right). C) Pre-tumoral spleens
from Tg8 mice accumulate CD4+CD8+ DP cells. Shown are
representative spleens from 4 week-old Tg8 and WT mice. D)
Normal splenic architecture in pre-tumoral 3 week-old Tg8
mice. Low power resolution confocal images of Tg8 (top) and
WT (bottom) frozen spleen sections. The white pulp can be
identified by T cell staining (anti-CD4 and anti-CD8) and B cell
staining (anti-B220), and the surrounding red pulp appears in
dark. White bar = 100 μm. E) High power resolution of the
PALS area of the spleen. Arrowheads point to some of the DP
cells. White bar = 6.25μm. F) Peripheral T cells in Tg8 mice,
but not WT mice, express surface DLL4. CD4 SP, CD8 SP and
DP cells, gated as in Figure 2C), were stained with anti-DLL4.
Representative of more than 20 mice.
doi: 10.1371/journal.pone.0084841.g002
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The Notch pathway is activated in DP cells of Tg8 mice
Given the over-expression of DLL4 on T cells, we
investigated the state of the Notch pathway in Tg8 mice.
Among the four Notch receptors, NOTCH1 plays a non-
redundant role in T cell development[9,39]. DP cells from
thymus and spleen of Tg8 mice had markedly higher surface
NOTCH1 expression than DP cells from WT thymus.
Interestingly, surface levels of NOTCH1 in Tg8 CD4 SP were
very similar to their WT counterparts, indicating a down-
regulation after the DP stage (Figure 3A). Next, we stained for
the activated form of NOTCH1, NICD. Tg8 DP cells had higher
NICD levels than Tg8 CD4 SP cells and WT CD4+ cells (Figure
3B). qPCR analysis of the expression of several Notch target
genes in purified DN, DP, CD4SP and CD8SP cells showed
that, in WT T cells, expression of Hes1, Heyl (Hrt3), and Ptcra
(Pre-Tα) undergoes a profound reduction as cells transition
from the DN to the DP stage. However, in Tg8 cells, expression
of Notch pathway target genes remained high at the DP stage
(Figure 3C). The expression of Notch target genes was
downmodulated in Tg8 SP cells, in agreement with the
downmodulation of the NOTCH1 receptor at the same stage
(Figure 3C). There is very good correlation between surface
NOTCH1 expression and its mRNA level in the different T cell
populations (Figure 3A and 3C) [40].. In order to test if DP cells
and/or SP cells were transformed malignant tumor cells, we
injected equal numbers of DP cells or SP cells at an early
tumoral step from the same Tg8 mice to the immuno-
compromised recipients. As shown in Figure 3D, all the
animals injected with Tg8 DP cells succumbed to T-ALL five
weeks after cell transfer, while the animals injected with SP
cells didn’t develop cancer. This indicates that Tg8 DP cells,
but not SP cells, are transformed malignant cells. Tg8 DN cells
had high NICD levels similar to Tg8 DP cells and WT thymic
DN cells (Figure 3E), indicating that DN cells in both Tg8 and
WT receive DLL4 signals and have activated Notch pathways.
We also determined the surface expression level of CD25,
another Notch target gene. In accordance to the NICD staining
and qPCR analysis of other Notch target genes, CD25
expression was elevated in Tg8 DP cells, but low in Tg8
CD4SP cells and WT cells (Figure S2A). All these results
clearly demonstrate that the Notch pathway is hyperactive at
DP stage of pre-tumoral Tg8.
In order to determine if the hyperactive Notch pathway led to
a higher cell division rate at the pre-tumoral stage, we
measured BrdU incorporation and carried out cell cycle
analysis with propidium iodide staining. We found no
differences between Tg8 and WT T cells, either in thymus,
spleen or LNs (Figure S2B and S2C) demonstrating that the
active Notch pathway did not promote cell cycle entry at the
pre-tumoral stage.
Blockade of the Notch pathway in Tg8 mice impairs
lymphoma development
To evaluate if eliminating the Notch pathway in Tg8 T cells
would stop T-ALL, we infected Tg8 hematopoietic stem cells
(HSC) with a retroviral construct harboring a short hairpin (sh)
against Dll4 (shDll4), and reconstituted irradiated RAG1-/- mice
with HSC infected with either shDll4 or the empty vector. Since
pre-tumoral Tg8 mice gradually accumulate DP cells in the
blood, we analyzed the percentage of DP cells among the
CD4+ T cells in blood every 10 days as a way to measure
progression of the disease. There was a clear delay in the
appearance of DP cells in mice reconstituted with shDll4-
infected HSC compared to those with empty vector-infected
HSC (Figure 4A), indicating that the rise of DP cells in Tg8
mice was driven by DLL4. However, DP cells were ultimately
observed in the blood of these mice, due to the fact that shDll4
reduced DLL4 expression only partially and temporarily (Figure
S2D and S2E). Four months after shDll4-HSC injection the
effect of the shDll4 had been totally lost (Figure S2E). The
temporal nature of the effect of the shRNA meant that a
different genetic approach was needed to permanently abolish
Notch signaling. We have previously shown that inactivation of
both PS1 and PS2 in T cells, using CD4-Cre PS1fl/fl PS2-/- mice
(PS KO CD4-Cre) [41], abrogated Notch signaling [4]. We
therefore crossed Tg8 mice with PS KO CD4-Cre mice.
Strikingly, these mice became resistant to TCL development.
From a group of 10 Tg8 PS KO CD4-Cre mice, only one mouse
developed TCL (Figure 4B), and this was the only animal that
Figure 3.  The Notch pathway is upregulated in DP cells of
Tg8 mice.  A) Notch1 receptor surface staining of Tg8 DP,
CD4 SP and WT DP in thymus (thy) or WT CD4+ T cells in
spleen (spl). B) Notch intracellular domain (NICD) staining of
Tg8 DP, CD4 SP and WT DP in thymus (thy) or WT CD4+ T
cells in spleen (spl). C) Thymic DN, DP and SP populations
from Tg8 mice and WT littermates were sorted and cDNA was
prepared for real time PCR analysis of the indicated genes.
Summary of quantitative real time PCR data from three
independent sorting experiments. Expression: - <5; +/- 5-15; +
15-50; ++ 50-100; +++ >100, normalized on β-actin expression
fixed at 10,000. The yellow shade highlights the DP
populations, which display the largest differences between WT
and Tg8 mice. D) 5x106 DP or SP cells were sorted from the
same Tg8 mice at the early tumorigenic stage, and injected to
nude mice. Survival rates of the recipients were recorded in the
following 5 weeks. E) NICD staining of Tg8 DN, DP, SP and
WT DN cells in thymus and spleen.
doi: 10.1371/journal.pone.0084841.g003
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retained a functional PS1fl allele (Figure 4C, lane labeled TCL,
non-deleted PS1 allele indicated by the arrowhead). In contrast
to Tg8 PS KO CD4-Cre mice, 19 of 19 Tg8 littermates that
either lacked CD4-Cre or were PS1fl/+ developed TCL.
Interestingly, Tg8 CD4-Cre PS1fl/+ PS2-/- mice showed a slight
delay in tumor onset compared to Tg8 CD4-Cre PS1+/+ PS2-/-
mice, probably due to lower Notch activation (Figure 4B).
Taken together, these results demonstrate that expression of
a functional Dll4 gene on the surface of T cells leads to Notch
pathway activation, causing T-ALL.
Swift transition from polyclonality to monoclonality in
Tg8 mice indicates secondary tumorigenic events
We took advantage of the complete penetrance of T-ALL in
Tg8 mice to study the pre-tumoral events. First, we determined
that the DP cells circulating in young Tg8 mice were polyclonal,
while the TCL were always clonal. Thus, at some point a DP
clone gains the advantage over the remaining DP cells. We
therefore studied the polyclonal to clonal (i.e. malignant)
transition in 13 Tg8 mice, all of which developed TCL.
Figure 4.  blockade of Notch signaling rescued Tg8 from
developing T-ALL.  A) Dll4 shRNA delays the onset of Tg8
lymphoma. The appearance of DP cells was monitored by
blood staining every 10 days. Data are presented as the
change in the DP/CD4 SP ratio over time. n=3 mice per group.
B) Conditional KO of γ-secretase in T cells eliminates Tg8
lymphomas. Survival curve of Tg8 PS KO (PS1fl/fl PS2-/-) CD4-
Cre mice (or PS1fl/+ as control) (n=10 animals per group). The
survival curve of 10 Tg8 mice was also recorded. Note that one
PS1fl/fl mouse escaped complete PS1 deletion (as shown in
panel C) and developed lymphoma. C) Efficiency of CD4-Cre-
mediated PS1 deletion in different purified thymic and splenic
cell populations. TCL: DNA from the only T cell lymphoma
observed in the Tg8 PS KO CD4-Cre group. Arrowhead: non-
deleted PS1 allele (Floxed).
doi: 10.1371/journal.pone.0084841.g004
By Vβ staining (6 of 13 TCL) and Vβ PCR (the remaining 7
TCL), we observed that all the Tg8 tumors expressed a single
Vβ (Figure 5A and data not shown). Figure 5A shows an
example of the rise of a Vβ6 clonal tumor, with concomitant
decrease of the frequency of Vβ8.1.2 T cells. The percentage
of DP cells in this mouse increased dramatically between day
50 and day 90, and the bulk of the increase could be attributed
to the rise of the clonal Vβ6 DP cells (Figure 5B).
To study the changes that accompany the transition to
malignancy in Tg8 T cells, we compared the rising clonal DP
cells with the remaining polyclonal DP cells from the same
animals; we chose day 90, an age in which both cell
populations could be sorted. We used the spleens of the 6
mice mentioned above with Vβ usage identifiable by antibodies
to study the expression of Notch target genes. In all cases, the
clonal DP cells expressed higher levels of Hes-1 and Deltex-1
than the polyclonal DP cells in the same mice (Figure 5C),
while DLL4 expression levels were not augmented (Figure 5D).
This confirms that the advent of malignancy is associated with
a further increase in Notch pathway activation in Tg8 mice.
Figure 5.  Swift transition from polyclonality to
monoclonality in Tg8 mice is associated with further
upregulated Notch.  A) Blood from Tg8 and WT mice was
drawn every 10 days starting at age 50d and stained with
different TCR Vβ antibodies. Shown are DP-gated T cells from
a case in which a Vβ6+ (top panel) TCL arose, with resulting
decrease in the proportion of Vβ 8.1.2 (bottom panel) T cells.
The Vβ usage in WT mice was calculated based on CD4+ T
cells. B) Accumulation of DP cells over time in the blood shown
in panel A). C) Clonality is associated with increased Notch
signaling. Thirteen Tg8 mice were followed as in Figure 3A with
a panel of Vβ antibodies: Vβ 3, 4, 5.1.2, 6, 7, 8,1,2, 8,3, 9, 12,
13 and 14. In six of these mice, the early clonal burst could be
identified by one of the listed Vβ antibodies. In these 6 mice,
clonal DP cells (Vβ +) and remaining polyclonal DP cells from
the same mice (Vβ-) were sorted. Expression of Hes-1 and
Deltex-1 was determined by qPCR. Shown is mean +/- SEM.
D) Tg8 tumor cells do not further up-regulate DLL4 expression.
Flow cytometry was carried out as in Figure 1. Mean
Fluorescence Intensity (MFI) was shown at the bottom.
doi: 10.1371/journal.pone.0084841.g005
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One possible explanation for the increase in Notch activity in
Tg8 TCL would be the NOTCH1 or FBW7 mutations. We
therefore sequenced the Notch1 and Fbw7 genes from 18 Tg8
TCL. None of the 18 had any of the known mutations (Figure
S3). However, four TCL had mutations, in all cases located in
Notch1 exon 34, which encodes the TAD and PEST domain.
Unlike the reported T-ALL-associated mutations, none of the 4
mutations resulted in truncation of the PEST domain.
The sharp transition from polyclonality to monoclonality that
we observed in Tg8 mice strongly suggests the existence of
secondary tumorigenic events, which further activate Notch
signaling. These secondary events are different from the
known Notch coding region mutations.
Presenilin-deficient Tg8 mice develop a non-malignant
lymphoproliferative disease
All Tg8 mice die of T-ALL by the age of 5 months with an
average of 4 months. As Tg8 PS KO CD4-Cre mice aged to
more than 7 months, they started to display enlarged LNs.
These animals ultimately developed a fatal lymphoproliferative
disease, with noticeable splenomegaly and enlarged LNs. The
thymi of the same mice were slightly smaller than that of their
control littermates (Figure 6A). It was possible that the
lymphoproliferative disease in Tg8 PS KO CD4-Cre was a
delayed T-ALL caused by incomplete deletion of the floxed
PS1 alleles. However, this was not the case, as we did not
observe the floxed PS1 band (Figure 6B).
We analyzed the cells that accumulated in 8-month old
moribund Tg8 PS KO CD4-Cre animals. Virtually all cells in the
spleen and the LNs of these animals were DP (Figure 6C). The
analysis of the Vβrepertoire showed that they were polyclonal,
while DP cells in Tg8 TCL were clonal (Figure 7A shows an
example of a Vβ8.1.2+ Tg8 TCL). This result suggested that the
lymphoproliferative disease in Tg8 PS KO CD4-Cre mice was
not cancer, but another form of lymphoproliferation. To test this
hypothesis, we transferred DP cells from Tg8 TCL (at 4 months
of age) or Tg8 PS KO CD4-Cre (at 8 months of age) mice into
nude recipients. After 3 to 4 weeks, all recipients of Tg8 TCL
died of T-ALL (Figure 7B). In contrast, the animals that
received Tg8 PS KO CD4-Cre DP cells remained free of
disease (Figure 7B), which confirmed that these polyclonal DP
cells were not transformed, malignant cells. Although these
polyclonal DP cells express DLL4, they have no Notch
signaling, and are not sustained as a population without
continuous overproduction from Notch-signaling competent
(pre-CD4) T cell precursors. Thus, two different types of
lymphoproliferative disease are observed in mice that express
DLL4 on T cells - a clonal, transferrable malignant disease and
a non clonal lymphoproliferative disease. Each of the two
outcomes is perfectly predictable based on the developmental
window in which the T cells are allowed to receive Notch
receptor-mediated signals.
CD4+ T cells from Tg8 mice support the extra-thymic DP
development of precursors
DLL4 is very important in T-development both in vitro and in
vivo [7]. We therefore reasoned that mature Tg8 cells, which
express DLL4 on their surface, drove T cell development in an
uncontrolled way. To demonstrate this, we transferred purified
CD4+ SP cells from pre-tumoral Tg8 or WT mice into nude
recipients [42]. Four weeks later, the spleens of nude mice that
received WT CD4+ T cells had CD4 SP cells only, and they
were of donor origin. In contrast, spleens of nude mice that
received CD4 SP cells from Tg8 animals displayed a clear DP
population (Figure 7C). The DP cells in nude recipients of Tg8
CD4 SP cells could be of Tg8 or nude origin. By polymorphism
in the Fox N1 gene we showed that DP cells were of nude
origin, while CD4 SP cells were of donor Tg8 origin (Figure
7D). We confirmed these results by DLL4 surface staining,
which showed that the CD4 SP cells expressed DLL4 (i.e. Tg8
origin) while the DP cells did not (i.e. nude origin) (Figure 7E).
Our results demonstrate that DLL4-expressing Tg8 T cells can
drive the T cell development in trans in vivo.
Discussion
Notch was discovered in mammals as a consequence of its
intracellular domain NICD being driven by the TCRβ
transcription regulatory elements, causing T-ALL in humans
[13]. Here we show that the Notch ligand DLL4 can cause T-
ALL when placed under the transcriptional control of the TCRα,
as occurred in Tg8 mice.
In the present work we report a mouse model showing that
Notch signaling on T cells can trigger two different types of
Figure 6.  Presenilin-deficient Tg8 mice develop a
lymphoproliferative disease.  A) Size and weight of
representative lymphoid organs obtained from 4 month-old Tg8
and 8 month-old Tg8 PS KO CD4-Cre and CD4-Cre mice. Note
the small size of the thymus in Tg8 PS KO CD4-Cre as
compared to Tg8 mice (lower panel). B) Complete Cre-
mediated deletion of PS1 in splenocytes from 4 month-old Tg8
PS KO CD4-Cre animals, as determined by PCR Analysis. C)
Expression of CD4 and CD8 in Tg8 or Tg8 PS KO CD4-Cre
splenocytes was examined the same time as 6A).
doi: 10.1371/journal.pone.0084841.g006
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Figure 7.  the lymphoproliferation in Tg8 PS KO CD4-cre is
non-clonal and non-transferable.  A) Mice harboring T cells
deficient in γ-secretase retain a polyclonal T cell repertoire. Vβ
antibody staining of gated CD4+ T cells of 8 month-old Tg8 PS
KO CD4-Cre and a Tg8 mouse of 4 months with a Vβ8.2+
lymphoma. B) Tg8 PS KO CD4-Cre T cells from A) do not
transfer malignancy, in contrast to the transfer of malignancy
by Tg8 splenic T cells from A), as shown in the survival curve
of nude recipient animals that were injected with 5x106 CD4+
splenocytes from Tg8 or Tg8 PS KO CD4-Cre mice. C) CD4
and CD8 staining profile of CD3+ splenocytes from nude
animals that were injected one month before with PBS (PBS),
WT CD4+ cells (CD4 WT) or Tg8 CD4 SP T cells (CD4 Tg8). D)
The origin of the different splenocyte populations in Figure 7C
was determined by Fox N1 gene profile. Tail DNA as template
was used for amplification and digestion of the control bands
for both WT and nude (NUDE). The non-digested PCR product
(without date) is also shown. MW: molecular weight markers.
E) Surface staining of DLL4 on CD4 SP and DP cells further
supports the nude origin (DLL4-negative) of DP cells.
doi: 10.1371/journal.pone.0084841.g007
diseases. One disease is T-ALL, a clonal, acute (as the name
indicates), transferrable disease. The second disease is a non-
clonal, non-transferrable lymphoproliferative disease with a
much slower progression than T-ALL, but ultimately also lethal.
T-ALL was the unavoidable outcome of Tg8 mice, a
consequence of continuous Notch signaling induced by DLL4
expression on all T cells, while in WT thymus DLL4 expression
is restricted to cortical epithelial cells (cTEC). Our results
strongly support the notion that the same DLL4-triggered Notch
pathway, which is essential for T cell generation at the DN
stage, is terribly harmful to the host if not shut down at the DP
stage as we forced in the Tg8 PSKO CD4-cre. Tg8 mice
display elevated NOTCH1 surface expression and its activated
form (NICD) only in DP cells, and, accordingly, DP cells
displayed the highest expression of Notch target genes.
Compared to the corresponding T cell populations in WT mice,
Tg8 mice display elevated expression of surface NOTCH1 and
the activated form NICD only in DP cells, and, accordingly, DP
cells displayed the highest expression of Notch target genes. In
addition, Tg8 DP cells were able to transfer the disease when
injected in nude mice while SP cells were not. Taken together,
out data suggest that DP cells are the ones at the origin of T-
ALL of Tg8 mice.
T-ALL in humans and experimental animals has been
correlated with increased Notch signaling, and T-ALL in Tg8
mice is no exception to this rule. There are however, new
features revealed by the Tg8 T-ALL model. First, the
expression of the Notch ligand DLL4 on T cells, by itself, is
sufficient to drive T-ALL in all mice with a short pre-tumoral
latency. In no case previously known was DLL4 expression
restricted to T cells. Instead, others used Dll4-transduced bone
marrow cells [29,30]. Second, we did not find any of the
mutations in Notch1 or Fbw7 that have been previously
associated with 50-60% of human T-ALL cases. However, 3
out 18 Tg8 lymphomas could be accounted for by mutations in
PEST domain Ser residues that are associated with
stabilization of NICD [43]. It remains the case that,
overwhelmingly, Tg8 TCL does not display the known T-ALL
mutations in the coding region. Interestingly, with no
exceptions, the malignant TCL further up-regulated Notch
signaling, indicating that secondary tumorigenic events took
place in single pre-tumoral cells that resulted in super-
increased Notch signaling and growth advantage over the
remaining pretumoral cells.
The polyclonal lymphoproliferative disease only occurred in
Tg8 PS KO CD4-Cre mice in which Notch signaling on T cells
was abrogated at the DP stage due to the CD4-Cre-mediated
deletion of PS1 (on a PS2 KO background). Lack of Notch
signaling at the DP stage eliminated malignant transformation.
In these Tg8 PS KO CD4-Cre mice, DP T cells were constantly
being produced due to DLL4-triggered Notch signaling of DN
cells, but, without Notch signaling on DP cells, there was no
transformation to a clonal, malignant state. These observations
have an implication on regular feed back mechanisms to
control T cell generation. In normal situations, T cell
development up to the DP stage is controlled by the limited
expression of DLL4 by cTEC, but in Tg8 and Tg8 PS KO CD4-
Cre mice, there is abundant DLL4 present on the surface of all
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T cells. Our results in nude animals, where Tg8 CD4 SP cells
but not WT CD4 cells promoted the development of DP cells of
nude origin clearly demonstrates that this DLL4-induced
pathway does not require a thymus, and that T cells expressing
DLL4 are highly competent to induce T cell development in vivo
up to the DP stage.
Human T-ALL has a more complex pattern with DN-like and
SP-like tumors observed and Notch1 mutations at different T-
cell maturation stages. In our model, DN cells are similar in WT
and Tg8 mice in regard to Notch signaling, as seen by Hes1
and Hrt3 expression (Figure 3C). However, in addition to the
physiologic thymic epithelial expression of DLL4, in Tg8 mice
and Tg8 PS KO mice, there is additional DLL4-mediated
triggering of Notch signaling, which is provided by the Tg8 DP
and SP T cells themselves (DN do not express DLL4 on their
surface but receive DLL4 signals). This excess signaling
actively promotes differentiation of the DN cells to DP without
malignancy, because DN cells are “used to” dealing with Notch,
and Notch is required for their differentiation. Malignancy only
arises when Notch signaling is un-physiologically carried on
into the DP stage, a stage in which Notch is normally shut
down, and then secondary mutations begin to occur and
accumulate. The former, the enhanced differentiation from DN
to DP, occurs in both Tg8 and Tg8 PS KO, but the latter, the
accumulation of secondary mutations and malignancy, only
occurs when Notch signaling is allowed to persist in the DP
stage, as in Tg8 mice but not Tg8 PS KO mice.
Our data helps explain the conflicting reports using bone
marrow cells retrovirally transduced with Dll4 [29,30]. While
Yan et al. reported T-ALL development, Dorsch et al. could not
obtain a single animal with T-ALL, although all the reconstituted
Dll4-expressing animals had a non-clonal, non-transferrable
lymphoproliferative disease. As retroviral expression was
differentially lost, Dll4 expression may have been shut down
earlier in the case of the Dorsch et al study, and be more
persistent in the T cell lineage in the Yan et al study.
Finally, our findings in Tg8 mice also offer a mechanism for
the phenomenon of donor cell leukemia. In these cases,
following allogeneic hematopoietic stem cell transplantation,
the host environment induces leukemia in healthy donor cells.
Depending on the study, it is estimated that between 0.1% and
5% of the post-transplant leukemia relapses in humans are
caused by donor cell leukemia [44-46]. Since we showed that
DLL4-expressing T cells from Tg8 mice could cause T cell
development in nude animals, it is tempting to speculate that,
in the Tg8 mouse model, a situation similar to donor cell
leukemia could be taking place. While ectopic Notch ligand
expression by host cells has not been looked at in correlation
with human donor cell T-ALL, our studies suggest that Notch
ligands may be good candidates to explain, in part, this
intriguing clinical phenomenon.
Supporting Information
Figure S1.  The cellular and genetic characterization of Tg8
tumors. A) Tg8 mice accumulate clonal DP cells. Tg8 tumors
are clonal as indicated by dominant usage of one Vβ in each
lymphoma (shown are 3 different 4 month-old Tg8 mice (#1,
#3, #5, left) comparing to WT littermates (#2, #4, #6, right). B)
More than 95% of tumors were CD4+CD8+DP but a small
percentage of tumors can display different CD4 and CD8
expression patterns (shown are 6 different Tg8 individuals with
lymphomas numbered #7 to #12). C) Tg8 mice have inserted a
single copy of the TCRα transgene, and the TCRα is not part of
any aberrant transcript. Left panel: Southern blot of DNA
extracted from Tg8, WT or Tg5 animals. The probes used are
indicated in Figure S1E. The arrows show the 5’ and 3’ flanking
sequences in Tg8. Right panel: northern blot probed with a Cα
probe and re-probed with β-actin. D) Diagram depicting (to
scale) the TCRα construct used to generate lymphoma-prone
Tg8 and lymphoma-free Tg5 mice. The position of the main
enhancer is indicated by a red box. The position of the 5’ and 3’
probes used in Figure S1D is indicated by blue rectangles
below the map. E) Summary of the transcriptional effects of
Tg8 insertion at Chromosome 2 for genes located between 100
and 250 kb on either side of the integration site. The thick line
between Exd1 and Cbp22 indicates the area closest to the
integration site (100 kb on each side). qPCR of the indicated
genes was performed, and the ratios of relative transcription
level of Tg8 tissue and WT tissue were calculated as listed in
the right three columns as thymus, spleen and T lymphoma
(TCL). The second and third columns to the left indicate
whether the raw expression values of the samples are hardly
detectable above the negative control (-), slightly above the
negative control (+/-), or clearly above the negative control (+).
All changes in expression ratios are non-significant. F)
Transcriptional effects of Tg8 insertion on the genes located
nearest the integration site (100 kb on each side). It is
noteworthy that Ino80 alone occupies more than half of this
region, and its promoter lies 134 kb away from the TCRα
enhancer in Tg8 mice. qPCR analysis was performed on cDNA
obtained from sorted T cells, sorted B cells, sorted brain
endothelial cells and Langerhans cells (LC cDNA from C57BL6
background as Tg8, a gift from Dr. Miriam Merad). For T and B
cells, data are presented as the ratio between the transcription
in Tg8 and WT cells. For endothelial cells and Langerhans
cells, the ratio is taken between these cells and WT T cells.
Data are represented as mean +/- SEM. G) Normal frequency
of B cells in spleen of 4 w.o pre-tumoral Tg8 mice analyzed by
flow cytometry.
(TIF)
Figure S2.  Proliferation profile of Tg8 T cells and the
efficiency of knock-down experiments. A) In Tg8 mice, the
Notch pathway is preferentially activated in DP cells. Shown is
the surface expression of the Notch target gene CD25 in the
indicated populations (color-coded). B) Four week-old Tg8 and
littermate controls were injected intraperitoneally with BrdU and
sacrificed 4 hours later. Thymic, splenic, and mesenteric lymph
node cells were surface-stained with anti-CD4 and anti-CD8
antibodies, followed by intracellular staining with anti-BrdU
antibody. The panel shows the percentage of BrdU+ cells
among the populations indicated in the x axis. Data are
represented as mean +/- SEM. C) Propidium iodide staining of
permeabilized thymic and lymph node cells from 3 week-old
Tg8 and WT littermate (n=3). D) CD4 SP splenocytes sorted
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from 4 week-old Tg8 were cultured and transduced with either
Dll4 shRNA-pQXIP/GFP vector or the same amount of empty
pQXIP/GFP vector. On day 3 the cells were analyzed for DLL4
surface expression with two gates on GFP+ and GFP-
populations. MFI= 12.9 in GFP- and 28.9 in GFP+ E) 4 week old
Tg8 BMs were transduced with either Dll4 shRNA or empty
vector, and transferred into RAG1-/- recipients. CD4 SP cells
from blood were analyzed for DLL4 expression at 3 and 4
months after BM transfer. Tg8 BM transduced with empty
vector was also transferred into RAG1-/- mice as positive
controls for lymphoma development; WT BM was transferred
into RAG1-/- mice as a negative control for lymphoma
development. MFI= 15.3 (empty vector), 12.6 (shRNA after 4
months), 7.3 (shRNA after 3 months), 1.7 (WT).
(TIF)
Figure S3.  None of the known T-ALL mutations of Notch1
or Fbw7 are found in Tg8 tumors. Lymphomas from 18
different Tg8 mice were analyzed by cDNA sequencing.
Primers were designed to amplify the designated exons of
Notch1 and Fbw7. PCR products were sent for sequencing,
and the data were aligned with WT as well as mutated Notch1
and Fbw7. Mutations were counted and identified.
(TIF)
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